{
  "drug_name": "Fusidic acid",
  "tradename": "Fucidin, Taksta",
  "usage_and_dosing": {
    "general": [
      "Major use of Fusidic acid is in the treatment of staphylococcal infections, including methicillin-resistant Staph. aureus (MRSA). Note: Staph. saprophyticus is intrinsically resistant.",
      "Steroid class drug with no corticosteroid activity; inhibits protein synthesis. Referred to as a Fusidane class antibiotic.",
      "Bacteriostatic.",
      "High level resistance due to mutations in the fusA gene that encodes the drug binding site in the ribosome.",
      "Fusidic acid is widely used in Europe and elsewhere, but is not, at present, marketed in the US. Clinical trials in the US are in progress.",
      "Active both extra- and intracellularly.",
      "Available as tablets, oral suspension, topical, ophthalmic, and IV solution.",
      "Activity enhanced in acidic media, accumulates in human cells; intracellular activity comparable to Linezolid and Clindamycin.",
      "Comprehensive review in supplement in Clin Infect Dis 52(Suppl 7):S542, 2011; Clin Infect Dis 52(Suppl 7):S467, 2011."
    ],
    "adult_dose": {
        "standard_european_regimen": "500 mg po/IV tid is standard European regimen. Internationally, available as 250 mg tablet. Availability of IV fusidic acid is uncertain.",
        "us_trials_regimen": "Day 1 loading dose of 1500 mg po bid and then 600 mg po bid (Clin Infect Dis 52(Suppl 7):S542, 2011)",
        "topical": "2% ointment, apply tid for impetigo"
    },
    "pediatric_dose": {
      "age_lt_1_yr": "50 mg/kg/day (divided q8h)",
      "age_1_5_yrs": "250 mg q8h",
      "age_6_12_yrs": "250-500 mg q8h",
      "age_gt_12_yrs": "adult dosing"
    }
  },
  "renal_adjustment": {
    "notes": [
        "Body weight and Creatinine Clearance calculations",
        "CrCl = Creatinine clearance (mL/min)",
        "CAPD = Continuous Ambulatory Peritoneal Dialysis",
        "CRRT = Continuous Renal Replacement Therapy",
        "AD = after hemodialysis",
        "SLED = sustained low efficiency dialysis",
        "Dosage adjustment may be required in hepatic disease."
    ],
    "half_life_normal": "8.9-11",
    "half_life_esrd": "Unchanged",
    "dose_normal_function": "500 mg po/IV q8h",
    "crcl_or_egfr": "No dosage adjustment for renal impairment",
    "hemodialysis": "No data",
    "capd": "No data",
    "crrt": "No data",
    "sled": "No data"
  },
  "hepatic_adjustment": {
    "mild_impairment_child_pugh_a": "No data",
    "moderate_impairment_child_pugh_b": "No data",
    "severe_impairment_child_pugh_c": "Avoid use"
  },
  "adverse_effects": [
    "Phlebitis with IV administration.",
    "Nausea, vomiting, diarrhea are most common with po administration.",
    "Elevated bilirubin due to inhibition of bile transport; much like Dubin-Johnson syndrome"
  ],
  "pregnancy_risk": {
    "fda_risk_category": null,
    "lactation": "Safety not established, avoid use",
    "footnote": "Capital letter = Old FDA risk category; Text = New FDA risk category"
  },
  "antimicrobial_spectrum": {
    "preferred": [],
    "alternative": []
  },
  "pharmacology": {
    "pk_pd_index": "No data",
    "preparations": "Tab (250 mg), Oral susp (50 mg/5 mL), 2% cream/ointment, 1% oph solution, Injection",
    "food_recommendation": "Tab + food",
    "oral_absorption_percent": "91",
    "tmax_hr": "2-4",
    "peak_serum_conc_ug_ml": "30 (500 mg po, SD)",
    "peak_urine_conc_ug_ml": "No data",
    "protein_binding_percent": "95-99",
    "volume_of_distribution_vd_l_kg": "0.3 L/kg",
    "avg_serum_half_life_hr": "15",
    "elimination": "Biliary",
    "bile_penetration_percent": "100-200",
    "csf_blood_percent": "No data",
    "therapeutic_levels_in_csf": "No data",
    "auc_ug_hr_ml": "442 (500 mg po, 0-inf)"
  },
  "enzyme_interactions": {
    "cyp450_substrate": ["CYP3A4"],
    "transporter_substrate": [],
    "ugt_substrate": [],
    "cyp450_inhibited": ["CYP3A4"],
    "transporters_inhibited": ["BCRP", "OATP1B1"],
    "ugts_inhibited": [],
    "cyp450_induced": [],
    "transporters_induced": [],
    "ugts_induced": [],
    "serum_drug_concentration_impact": "↑"
  },
  "major_drug_interactions": [
      {
          "drug": "Atorvastatin",
          "effect": "↑ atorvastatin (↑ risk of rhabdomyolysis)",
          "management": "Avoid co-administration"
      },
      {
          "drug": "Rifampin",
          "effect": "↑ rifampin, ↓ fusidic acid",
          "management": "Monitor or avoid"
      },
      {
          "drug": "Ritonavir",
          "effect": "↑ fusidic acid",
          "management": "Monitor or avoid"
      },
      {
          "drug": "Simvastatin",
          "effect": "↑ simvastatin (↑ risk of rhabdomyolysis)",
          "management": "Avoid co-administration"
      }
  ],
  "comments": [
    "Reserved for staphylococcal infections resistant to other drugs or for patients intolerant or allergic to other drugs.",
    "Report of 8 cases of rhabdomyolysis after concomitant use of statin and fusidic acid (BMJ 345:e6562, 2012)."
  ]
}
